​

United Therapeutics (UTHR) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

UTHR Stock Forecast

United Therapeutics (UTHR) stock forecast, based on 30 Wall Street analysts, predicts a 12-month average price target of $539.83, with a high of $587.00 and a low of $447.00. This represents a 10.48% increase from the last price of $488.62.

$200 $280 $360 $440 $520 $600 High: $587 Avg: $539.83 Low: $447 Last Closed Price: $488.62

UTHR Stock Rating

United Therapeutics stock's rating consensus is Buy, based on 30 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 16 Buy (53.33%), 13 Hold (43.33%), 1 Sell (3.33%), and 0 Strong Sell (0.00%).

Buy
Total 30 1 13 16 Strong Sell Sell Hold Buy Strong Buy

UTHR Price Target Upside V Benchmarks

TypeNameUpside
StockUnited Therapeutics10.48%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts1712
Avg Price Target$575.00$531.14$501.75
Last Closing Price$488.62$488.62$488.62
Upside/Downside17.68%8.70%2.69%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 25185--14
Nov, 25375--15
Oct, 25375--15
Sep, 25275--14
Aug, 25275--14
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 19, 2025Eun YangJefferies$575.00$476.5920.65%17.68%
Oct 30, 2025Andrew FeinH.C. Wainwright$525.00$449.7616.73%7.45%
Oct 30, 2025Lisa WalterRBC Capital$587.00$449.7630.51%20.13%
Oct 29, 2025Terrance FlynnMorgan Stanley$447.00$449.70-0.60%-8.52%
Oct 10, 2025Terence FlynnMorgan Stanley$435.00$445.38-2.33%-10.97%
Sep 29, 2025UBS$580.00$432.6634.05%18.70%
Sep 26, 2025RBC Capital$569.00$427.1633.21%16.45%
Sep 10, 2025Olivia BrayerCantor Fitzgerald$525.00$396.5032.41%7.45%
Sep 05, 2025Andrew FeinH.C. Wainwright$500.00$400.5224.84%2.33%
Sep 02, 2025Roger SongJefferies$564.00$404.8139.32%15.43%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Nov 19, 2025JefferiesBuyBuyhold
Oct 30, 2025H.C. WainwrightBuyBuyhold
Oct 30, 2025RBC CapitalOutperformOutperformhold
Oct 29, 2025JefferiesBuyBuyhold
Sep 29, 2025UBSBuyBuyhold
Sep 26, 2025RBC CapitalOutperforminitialise
Sep 10, 2025Cantor FitzgeraldOverweightOverweighthold
Sep 05, 2025OppenheimerOutperformOutperformhold
Sep 04, 2025UBSBuyBuyhold
Sep 02, 2025JefferiesBuyBuyhold

Financial Forecast

EPS Forecast

$10 $21 $32 $43 $54 $65 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$11.65$10.60$15.98$21.04$26.44----
Avg Forecast$12.77$11.38$17.52$19.75$24.31$28.54$29.58$39.69$34.70
High Forecast$13.57$12.10$18.72$21.10$28.47$34.53$41.57$61.71$37.76
Low Forecast$11.69$10.42$15.82$18.78$22.59$22.69$17.20$23.50$30.22
Surprise %-8.77%-6.85%-8.79%6.53%8.76%----

Revenue Forecast

$1B $2B $2B $3B $4B $5B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.48B$1.69B$1.94B$2.33B$2.88B----
Avg Forecast$1.46B$1.70B$1.96B$2.29B$2.88B$3.17B$3.37B$3.87B$4.11B
High Forecast$1.53B$1.78B$2.07B$2.33B$2.95B$3.38B$3.38B$3.96B$4.39B
Low Forecast$1.37B$1.59B$1.82B$2.26B$2.84B$2.87B$3.36B$3.78B$3.70B
Surprise %1.57%-0.73%-1.35%1.66%0.02%----

Net Income Forecast

$0 $700M $1B $2B $3B $4B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$514.80M$475.80M$727.30M$984.80M$1.20B----
Avg Forecast$481.19M$484.39M$532.82M$984.80M$1.27B$1.30B$1.29B$1.61B$1.72B
High Forecast$577.43M$581.26M$639.39M$1.18B$1.42B$1.72B$2.07B$3.07B$1.88B
Low Forecast$384.95M$387.51M$426.26M$787.84M$1.12B$1.13B$854.73M$1.17B$1.50B
Surprise %6.98%-1.77%36.50%--5.83%----

UTHR Forecast FAQ

Is United Therapeutics stock a buy?

United Therapeutics stock has a consensus rating of Buy, based on 30 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 16 Buy, 13 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that United Therapeutics is a favorable investment for most analysts.

What is United Therapeutics's price target?

United Therapeutics's price target, set by 30 Wall Street analysts, averages $539.83 over the next 12 months. The price target range spans from $447 at the low end to $587 at the high end, suggesting a potential 10.48% change from the previous closing price of $488.62.

How does United Therapeutics stock forecast compare to its benchmarks?

United Therapeutics's stock forecast shows a 10.48% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for United Therapeutics over the past three months?

  • December 2025: 7.14% Strong Buy, 57.14% Buy, 35.71% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 20.00% Strong Buy, 46.67% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 20.00% Strong Buy, 46.67% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.

What is United Therapeutics’s EPS forecast?

United Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $28.54, marking a 7.94% increase from the reported $26.44 in 2024. Estimates for the following years are $29.58 in 2026, $39.69 in 2027, and $34.7 in 2028.

What is United Therapeutics’s revenue forecast?

United Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $3.17B, reflecting a 10.19% increase from the reported $2.88B in 2024. The forecast for 2026 is $3.37B, followed by $3.87B for 2027, and $4.11B for 2028.

What is United Therapeutics’s net income forecast?

United Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $1.3B, representing an 9.12% increase from the reported $1.2B in 2024. Projections indicate $1.29B in 2026, $1.61B in 2027, and $1.72B in 2028.